Compare Incyte Corporation (INCY) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Mattel Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Mattel Inc trades at $16.68 (market cap $4.74B). The key difference: Incyte Corporation is far larger — about 4.8× Mattel Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Mattel Inc for 97 Days on average.
| INCY | MAT | |
|---|---|---|
Market Cap | $22.85B | $4.74B |
Volume | 1,927,029 | 11,809,722 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $22.16 |
52-Week Low | $83.80 | $12.66 |
Typical Hold Time | 33 Days | 97 Days |
Enterprise Value | $18.35B | $6.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Mattel (MAT) trades at $17.12, up 4.58% amid takeover speculation from Authentic Brands Group. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, the company maintains solid profitability with 7.78% net margins and 20.5% ROE, though recent earnings have been mixed with two misses in the last three quarters. Leadership transition is underway with Roger Lynch replacing Ynon Kreiz as CEO.
The takeover interest creates near-term upside potential, but execution risks remain under new leadership. Analyst consensus is bullish with 53% buy ratings and $15 price target, though current price exceeds target. Key risks include Barbie sales deterioration, integration challenges for new CEO, and declining operating cash flow from $870M in 2023 to $593M in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
